The National Health Surveillance Agency (Anvisa) revoked this Wednesday (19) the import registration of the Taffix antiviral nasal spray manufactured by the Israeli biopharmaceutical Nasuspharma and distributed in Brazil by Belcher Farmacêutica.
As stated by Belcher in a public note, the Taffix antiviral spray is able to block respiratory viruses in the nasal cavity, including the Sars-CoV-2 and Influenza, by creating an active antiviral barrier to protect and deactivate aerosol-transmitted viruses.
Ec onomy and market 19 Jan
Tech
12 Jan
Despite the statement, the pharmaceutical company was unable to attest to the safety and efficacy of the product through clinical studies sent to Anvisa and, as a result, had his notification authorization canceled by the agency, a decision that was published in the Official Federal Gazette (DOU) of today, 19, and took effect immediately.
As the Brazilian agency explained, the so-called “authorization to notify ção” allows to regulate the import of products belonging to risk classes I, II and that are related to health, dispensing with the prior technical analysis for regularization, but which can be canceled suddenly.
Note: This article has been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here